Sir Pant Immunotherapeutics
Research, 1214 Research BLVD, Hummelstown, Pennsylvania, 17036, United States, 1-10 Employees
Phone Number: +16*********
Who is SIRPANT IMMUNOTHERAPEUTICS
SIRPant Immunotherapeutics is spearheading the development of macrophage-based cell therapies for the treatment of solid tumors. Leveraging our deep understanding of the biology of myeloi...
Read More
-
Headquarters: 1214 Research BLVD, Hummelstown, Pennsylvania, 17036, United States
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
Industry: Research
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from SIRPANT IMMUNOTHERAPEUTICS
SIRPant Immunotherapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding SIRPant Immunotherapeutics
Answer: SIRPant Immunotherapeutics's headquarters are located at 1214 Research BLVD, Hummelstown, Pennsylvania, 17036, United States
Answer: SIRPant Immunotherapeutics's phone number is +16*********
Answer: SIRPant Immunotherapeutics's official website is https://sirpantimmunotx.com
Answer: SIRPant Immunotherapeutics's revenue is $1 Million to $5 Million
Answer: SIRPant Immunotherapeutics's SIC: 8731
Answer: SIRPant Immunotherapeutics has 1-10 employees
Answer: SIRPant Immunotherapeutics is in Research
Answer: SIRPant Immunotherapeutics contact info: Phone number: +16********* Website: https://sirpantimmunotx.com
Answer: SIRPant Immunotherapeutics is spearheading the development of macrophage-based cell therapies for the treatment of solid tumors. Leveraging our deep understanding of the biology of myeloid cellsthe cells that drive immune responsesSIRPant engineers specially-equipped macrophages from a patients own blood cells without any genetic modifications and then provides those cells back to the patient. In pre-clinical studies, this approach has been shown to generate polyclonal tumor neo-antigen-specific killer T cell responses as well as polyclonal tumor neo-antigen-specific antibody responses, leading to complete resolution of treated tumors. This also yields an adaptive immune response that is elaborated in space (targeting metastatic lesions) and time (providing long-term immunity to prevent recurrence). In addition, because this therapeutic approach does not target specific singular tumor-associated antigens, SIRPant technology provides a highly modular platform that is applicable across many solid tumor types, without requiring pre-identification of target tumor antigens in the patient.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month